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                             Generat Introduction
    In the terminal phase ofthe cancer, the management ofchronic pain is an essential factor
in a comprehensive strategy for palliative care. In populations with solid tumors, the overall
prevalence of clinically significant chronic pain ranges from 150/o to more than 750/o,
depending on the type and extent of disease and many other factors i). According to
international comparisons of the use of medical narcotics, morphine consumption has been
increasing each year in many countries. However, morphine consumption per capita in
Japan is still less than those in other developed countries 2). It is well known that morphine
induces rewarding effects in animals, and has been abused in humans. Opioids such as
morphine frequently produce a syndrome that includes feelings of euphoria, and this may be
related to their abuse. Thus, clinicians may hesitate to prescribe morphine.
    According to a statement from the World Health Organization (WHO), "palliative care"
is an approach that improves the quality of life (QOL) ofpatients and their families facing the
problems associated with life-threatening illness, through the prevention and relief of
suffering by the early identification and impeccable assessment and treatment of pain and
other problems, including physical, psychosocial and spiritual pain 3). A previous study
indicated that among patients with metastatic non-small-cell lung cancer, early palliative care
led to significant improvements in both QOL and mood. Compared with patients who
received standard care, patients who received early palliative care required less aggressive
care at the end of life, but experienced longer survival 4). Conversely, palliative treatments
may be used to improve the side effects of medicinal treatments, such as by relieving the
gastrointestinal side effects associated with opioid analgesics. Gastrointestinal side effects
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such as nausea and vomiting are commonly associated with the administration of opioid
analgesics and represent a significant cause of patient discomfort and dissatisfaction with
treatment 5). The incidence ofnausea and vomiting reported in patients treated with opioids
for chronic pain in a clinical trial setting ranges from 100/o to 500/o 6-9). Various stimuli that
lead to nausea and vomiting act on the "vomiting center" in the medulla oblongata of the
brain iO). Nausea and vomiting are usually initiated by peripheral irritant stimuli acting on
the gastrointestinal tract, which are transduced into sensory signals that are transmitted
centrally to the vomiting center by vagal and sympathetic afferent nerves. The vomiting
center receives input from four major areas: the chemoreceptor trigger zone (CTZ) for
vomiting, the gastrointestinal tract, the vestibular apparatus in the temporal lobe, and the
cerebral cortex. The clinical situation is often complicated by the variety of different
opioid-related emetogenic mechanisms. Opioids exert emetogenic effects through multiple
mechanisms, principally involving three of these areas; i.e., direct stimulation of the CTZ,
inhibition of the gastrointestinal tract, and stimulation of the vestibular apparatus ii). The
mechanism of the opioid-induced stimulation of the CTZ involves the activation of pt and 6
opioid receptors i2), and signaling to the vomiting center occurs primarily via dopamine D2
receptors as well as serotonin3 (5•-HT3) receptors present in the CTZ. On the other hand, it
has been postulated that histamine Hi receptors and muscarinic acetylcholine receptors are
responsible for opioid-induced stimulation ofthe vestibular apparatus. Furthermore, sensory
input to the vomiting center occurs via histamine Hi and muscarinic acetylcholine pathways
i3). In addition, the emetic reflex is regulated by the dorsal vagal complex (DVC) in the
brainstem. The DVC includes the area postrema, the nucleus ofthe solitary tract (NTS), and
the dorsal motor nucleus of the vagus (DMN) i4). The DVC is also the major site of
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termination of vagal afferent fibers from the gut i5). An autoradiography analysis
demonstrated that muscarinic cholinergic receptors are present on terminals of vagal afferent
neurons that project to these specific brainstem regions i6). Nausea and vomiting effects are
more difficult to control completely in the majority ofpatients i7). Many clinicians consider
that dopamine receptor antagonists are the preferred drugs for combatting opioid-induced
emesis i8'i9). However, these drugs often produce adverse effects, including extrapyramidal
symptoms (EPS). EPS are various movement disorders such as acute dystonic reactions,
pseudoparkinsonism, or akathisia that often affect the patient's QOL 20). Therefore, the
development of new antiemetic drugs with improved risk-benefit profiles is required for
chronic pain management. Regarding this issue, atypical antipsychotics such as olanzapine
have been used for the treatment of schizophrenia as a serotonin-dopamine antagonist, and
relatively lack EPS 2i). Therefore, olanzapine may be usefu1 as an adjunct for treatment with
morphine. However, the combined effects ofmorphine and olanzapine on the antinociceptive
and side effects of morphine have not been examined.
    On the other hand, neuropathic pain is the most difficult pain to manage in the pain clinic,
and is characterized by spontaneous burning pain, hyperalgesia (exaggerated pain in response
to painfu1 stimuli) and allodynia (pain caused by normally innocuous stimuli). Additionally,
patients who suffer from neuropathic pain andlor cancer pain commonly experience sleep
disturbance 22-24). It is considered that sleep disturbance itseJf may aggravate pain. Thus,
medical treatment for protecting agent such sleep disturbance may be beneficial in these
Patients 24).
    Moreover, a large and growing body of evidence has demonstrated that activation of the
dopaminergic, especially mesolimbic, system plays a crucial role in the expression of the
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reinforcing f' rewarding effects of opioids. Especially, hyperlocomotion and the conditioned
place preference induced by morphine have been used to assess the underlying
pharmacological profiles or mechanism of the abuse of morphine 25). On the other hand,
morphine induces several kinds of subjective and psychotic effects in humans. The method
that has been developed to assess the subjective effects in human is the drug discrimination
procedure 26). Nevertheless, the mechanism ofthe discriminative stimulus effects ofmorphine
has not yet been well characterized. Before we can claim that olanzapine is effective as an
adjunct for morphine, the effects of olanzapine on the several behavioral effects induced by
morphine should also be addressed.
4
                               Aim and Scope
    The aim of the present study was to investigate the utility of the combination of
morphine with atypical antipsychotic olanzapine for pain therapy. Therefore, behavioral
experiments were conducted in the present study.
The specific aims ofthe proposed research are:
In Chapter 1:
    Olanzapine is an atypical antipsychotic that blocks dopaminergic, serotonergic,
adrenergic, histaminergic, and muscarinic receptors for multiple neurotransmitters. Since it
affects multiple neurotransmitters that are associated with nausea, I hypothesized that it may
have potential as an antiemetic medication.
    Therefore, I investigated whether the olanzapine could suppress morphine-induced
emesis and alleviate sleep dysregulation associated with neuropathic pain without producing
side-effects.
In Chapter 2:
    To further examine whether the olanzapine suppresses morphine abuse potential, I
investigated whether olanzapine could suppress the several behavioral effects such as
hyperlocomotion, rewarding effect and discriminative stimulus effect induced by morphine.
5
Ethics
    The present study was conducted in accordance with the Guiding Principles for the Care
and Use of Laboratory Animals at Hoshi University, as adopted by the Committee on Animal
Research of Hoshi University, which is accredited by the Ministry of Education, Culture,
Sports, Science, and Technology of Japan. Every effort was made to minimize the number
and suffering of animals used in the following experiments.
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Chapter1
Usefulness of olanzapine as an adjunct to opioid treatment
treatment of neuropathic pain
and for the
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Introduction
    The WHO 27) has stated that morphine is the "gold standard" for the treatment of
moderate to severe pain caused by cancer. However, the use ofmorphine for this purpose is
often associated with distressing side effects, such as drowsiness, constipation, emesis, and
delirium i8'i9). Many clinicians consider that dopamine receptor antagonists, including
prochlorperazine, are the preferred drugs for combatting opioid-induced nausea and vomiting
i8'i9). However, these drugs often produce adverse effects, including extrapyramidal
symptoms 20). Therefore, new approaches are needed to prevent opioid-induced emesis, as is
a better understanding of the mechanism of drug action.
    Nausea and vomiting are controlled by the "vomiting center" in the medulla oblongata iO),
which receives signals from the CTZ in the area postrema, the gastrointestinal tract, the
vestibular apparatus in the temporal lobe, and the cerebral cortex 5). Opioids have
emetogenic effects by stimulating the CTZ and the vestibular apparatus, and by inhibiting gut
motility ii). wnile stimulation ofthe CTZ by opioids involves opioid pt and 6 receptors i2),
signals from the CTZ to the vomiting center mainly involve dopamine D2 and serotonin3
(5-HT3) receptors in the former. However, opioid-induced stimulation ofthe vestibular
apparatus and subsequent sensory input to the vomiting center have both been suggested to
involve histamine Hi and muscarinic acetylcholine pathways i3).
    Atypical antipsychotic medications treat the positive symptoms ofschizophrenia, such as
hallucinations and delusions, more effectively than the negative symptoms, such as lack of
motivation and social withdrawal. Olanzapine is a newer atypical antipsychotic that blocks
dopaminergic, serotonergic, adrenergic, histaminergic, and muscarinic receptors for multiple
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neurotransmitters. Because it affects neurotransmitters that are associated with nausea, it
may have potential as an antiemetic medication 28).
    In addition, patients with chronic pain commonly experience sleep disturbance 22'24), and
may benefit from its treatment 24). Sleep problems and daytime sleepiness seem to be related
to depression and the severity ofpain 29). It has been suggested that olanzapine may improve
sleep disturbance 30).
    The primary endpoint ofthe study was to investigate whether olanzapine at doses lower
than those that would induce catalepsy could suppress morphine-induced emesis with few
side effects. I also examined ifolanzapine could improve sleep dysregulation under a
neuropathic pain-like state.
9
                          Materials and Methods
Animals
    In the present study, male Institute of Cancer Research mice (20 - 25 g) (Tokyo
Laboratory Animals Science Co. Ltd, Tokyo, Japan), male C57BL16J mice (25 - 30 g) (CLEA
Japan, Inc., Tokyo, Japan) and Sprague-Dawley rats (200 - 300 g) (Tokyo Laboratory
Animals Science Co. Ltd) were used. Animals were housed in a room maintained at 220 Å}
1 OC with a 12-h light-dark cycle. Food and water were available ad libitum. Each animal
was used only once. Male ferrets weighing 1 - 1.5 kg were obtained from Marshall
Research Labs (North Rose, NY) and housed individually in a room kept at 230 Å} 1 OC under
a 12-h light-dark cycle (lights on 8:OO AM - 8:OO pM). They were given a standard cat diet (70
-
 80 glanimal, Oriental Yeast Co. Ltd, Chiba, Japan) and allowed free access to water.
Receptor binding assay
    Mouse whole-brain was treated as described previously 3i), and the resulting pellet was
resuspended and used as the membrane fraction. The binding assay was performed in
triplicate with [3H]clozapine (specific activity, 70 - 87 Ci!mmol; American Radiolabeled
Chemicals Inc., St Louis, MO) at O.2 nM, [3H]ketanserin hydrochloride (specific activity, 67
Cilmmol; PerkinElmer, Inc., Waltham MA) at O.5 nM, [3H] BRL-43694 (granisetron)
(specific activity, 85.3 Cilmmol; PerkinElmer, Inc.) at O.5 nM, [3H]GRI13808 (specific
activity, 78.3 Cilmmol; PerkinElmer, Inc.) at O.5 nM, [3H]pyrilamine (specific activity, 30
Ci/mmol; PerkinElmer, Inc.) at O.5 nM, and [3H]pirenzepine (specific activity, 72.8 Cilmmol;
PerkinElmer, Inc.) at O.5 nM, in a final volume of 500 ml that contained 50 mM Tris-HCI
buffer, pH 7.4, and 200 ml of the homogenized membrane fraction. Ninety to 140 mg of
membrane proteins were used in each assay. Specific binding was defined as the difference
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in binding observed in the absence and presence of 1 mM unlabeled clozapine, ketanserin,
granisetron, or GRI13808, 10 mM unlabeled pyrilamine, or 100 mM unlabeled pirenzepine,
respectively. All samples were incubated as described previously 3i), and radioactivity in the
samples was determined with a liquid scintillation analyzer. All receptor binding curves
were fitted using Prism software (version 5.0a, GraphPad Sofuvare, Inc., La Jolla, CA).
Evaluation of the emetic response
    Emesis in ferrets after the administration of morphine (O.6 mglkg, subcutaneous
injection) was evaluated by counting the number of retching or vomiting behaviors as
described elsewhere 32), where retching was defined as a rhythmic abdominal contraction
without expulsion and vomiting was the oral expulsion of solid or liquid from the
gastrointestinal tract. Emesis was assessed for 30 min after the injection of morphine 33).
To determine the effect of olanzapine on morphine-induced emesis, groups of ferrets were
pretreated with olanzapine 30 min prior to the injection ofmorphine.
    An interval of at least 7 days was allowed between testing for each animal to allow for
drug washout and to minimize the development oftolerance.
Horizontal Bar Test for the Evaluation of Catalepsy
    catalepsy 34'35) was evaluated using the horizontal bar test as described previously 36).
Briefly, animals were placed so that both forepaws were over a horizontal bar 5 cm above the
floor, and the amount of time (s) that the animal maintained this position was recorded for up
to 60 s. Catalepsy was considered to have finished when a forepaw touched the floor or
when the mouse climbed on the bar. Scores were assigned based on the duration of the
cataleptic posture (score 1: between 15 to 29 s, score 2: between 30 to 59 s, score 3: 60 s or
more).
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In vivo microdialysis study and quantification of dopamine and its metabolites
    After 3 days ofhabituation to the main animal colony, all of the rats were anesthetized
with sodium pentobarbital (50 mgtkg, intraperitoneal administration) for surgery as described
previously 36). Briefly, the anesthetized animals were placed in a stereotaxic apparatus, the
skull was exposed and a small hole was made using a dental drill. A guide cannula (AG-8;
Eicom, Kyoto, Japan) was implanted into the nucleus accumbens (from the bregma: anterior,
+4.0 mm; lateral, -O.8 mm; ventral, -6.8 mm; angle 160) according to the atlas ofPaxinos and
Watson 37), and fixed to the skull with cranioplastic cement. Three to 5 days after surgery,
microdialysis probes (A-I-8-02; 2mm membrane length; Eicom) were slowly inserted into the
nucleus accumbens through guide cannulas during anesthesia with diethyl ether, and the rats
were placed in experimental cages (30 cm wide x 30 cm deep x 30 cm high). The probes
were perfused continuously (2 ml/min) with artificial cerebrospinal fluid: O.9 mM MgCl2,
147.0 mM NaCl, 4.0 mM KCI, and 1.2 mM CaC12. 0utflow fractions were collected every
20 min. After three baseline fractions were collected from the rat nucleus accumbens, rats
were given olanzapine (O.3 mglkg, intraperitoneal administration), vehicle (5 O/o dimethyl
sulfoxide [DMSO]); 1 mllkg, intraperitoneal administration) or saline (1 mllkg,
intraperitoneal administration) 30 min before treatment with morphine (10 mg/kg,
intraperitoneal administration). Dialysis samples were collected for 180 min after treatment
and analyzed by high-performance liquid chromatography (Eicom) with electrochemical
detection (ECD, Eicom). Dopamine and its metabolites, 3,4-dihydroxyphenylacetic acid and
3-methoxy-4-hydroxyphenyl acetic acid, were separated by column chromatography, and
identified and quantified by the use of standards, as described previously 36).
12
Gastrointestinal transit
    In the study of gastrointestinal transit 38), Institute of Cancer Research mice were fasted
for 12-h before the experiments. Groups ofmice were pretreated with olanzapine (O.03 to 1
mglkg, subcutaneous injection) or vehicle (50/o DMSO) 30 min before the administration of
morphine (O.7 mgtkg, subcutaneous injection) or saline, and ink (O.3 mllmouse) was orally
administered 20 min after the injection of morphine or saline. Twenty min after the
administration of ink, the animal was killed by cervical dislocation, and the small intestine
was removed. The percentage inhjbition ofgastrointestjnal transit was caJculated as follows:
(distance traveled by the ink 1 length from the pylorus to the cecum) Å~ 1OO.
Blood glucose level measurement
    C57BL16J mice were administered olanzapine (O.03 - 1 mglkg, subcutaneous injection)
or vehicle (50/o DMSO) once a day for1 week. At 60 min after the final injection, the tail
was cut and blood was collected. Blood glucose was measured using a self-monitoring
blood glucose meter (Medisafe-Mini, Terumo, Tokyo, Japan). The Medisafe-Mini system is
based on the optoelectric colorimetry method.
Neuropathic pain model
    C57BL!6J mice were anesthetized with 30/o isofiurane. A partial sciatic nerve ligation
model was made by tying a tight ligature with 8-O silk suture around approximately one third
to one half the diameter of the sciatic nerve on the right side (ipsilateral side) under a light
microscope (SD30; Olympus, Tokyo Japan). In sham-operated mice, the nerve was exposed
without ligation.
13
Measurement of thermal thresholds
    The sensitivity to thermal stimulation was measured as described previously 39). Briefly,
the right plantar surface of mice was exposed to a well-focused radiant heat light source
(model 33 Analgesia Meter; IITCILife Science Instruments, Woodland Hills, CA) that had
been adjusted so that the average baseline latency of paw-withdrawal in naive mice was
approximately 8 - 10 s. Only quick movements of the hind paw away from the stimulus
were considered to be a withdrawal response: paw movements associated with locomotion or
weight shifting were not counted as a response. The paws were measured alternating between
left and right with an interval of more than 3 min between measurements. Before testing,
mice were placed in a clear acrylic cylinder (15 cm high and 8 cm in diameter) for at least 30
min. The data represent the average latency ofpaw-withdrawal for the right hind paw.
EIectroencephalogram and electromyogram recordings
    Electroencephalogram and electromyogram recordings were obtained as described
previously 39). Briefiy, electroencephalogram signals were monitored with two
stainless-steel electroencephalogram recording screws 1 mm anterior to the bregma or X, both
1.5 mm lateral to the midline, and electromyogram activity was monitored by stainless steel,
nonstick-coated wires placed bilaterally into both trapezius muscles. Electroencephalogram
and electromyogram signals were amplified, filtered (O.5 - 30 Hz and 20 - 200 Hz,
respectively), digitized at a sampling rate of 128 Hz, and recorded using SLEEPSIGN
software (Kissei Comtec, Nagano, Japan), which was also used to automatically classify
vigilance over 4-sec epochs as wakefulness, rapid eye movement (REM) sleep, or non-REM
sleep using standard criteria. Finally, defined sleep-wake stages were examined visually
and corrected, if necessary. For each epoch, the electroencephalogram power density in the
6 (O.75 - 4.0 Hz) and e bands (6.25 - 9.0 Hz) and the integrated electromyogram value were
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displayed on a computer monitor. Electroencephalogram and electromyogram activities
were monitored for 24-h at 7 days after sciatic nerve ligation. Recordings were started at
8:OO pM. Vehicle (5 O/o DMSO) or olanzapine (O.06 mglkg, intraperitoneal administration)
was injected every day at 8:OO AM.
Drugs
    The drugs used in the current study were morphine hydrochloride (Daiichi-Sankyo,
Tokyo, Japan), prochlorperazine maleate (Sigma-Aldrich Co., St Louis, MO), clozapine
(Wako Pure Chemical Industries, Osaka, Japan), olanzapine (Toronto Research Chemicals,
Toronto, Ontario, Canada), telenzepine dihydrochloride hydrate (Sigma-Aldrich), ritanserin
(Tocris Biotechnology, Ellisville, CA), pyrilamine maleate salt (Sigma-Aldrich), ketanserin
tartrate (Wako Pure Chemical Industries), granisetron (Sigma-Aldrich), GRI13808
(Sigma-Aldrich), haloperidol (Sigma-Aldrich), L745870 (Research Biochemicals
International Natick, MA), raclopride (Santa Cruz Biotechnology, Santa Cruz, CA),
pirenzepine (Toronto Research Chemicals), and DL-trihexyphenidyl hydrochloride
(Sigma-Aldrich).
Statistical Analysis
    Data are expressed as the mean with S.E.M. The statistical significant of differences
between the groups was assessed with one-way and two-way ANOVA followed by the
Bonferroni multiple comparisons test or Student's t-test (unpaired, two-tailed). The
concentration of the test compound that caused 50 O/o inhibition of specific binding (ICso
value) was determined from each concentration-response curve. All statistical analyses and
ICso values were calculated by Prism software (version 5.0a, GraphPad Software, Inc., La
Jolla, CA). A p value ofÅq O.05 was considered to reflect significance.
                                       15
Results
Binding properties of clozapine
    In mouse brain membranes, I determined the competitive displacement binding of
[3H]clozapine with graded concentrations (1O'ii to 10-4 M) ofunlabeled clozapine, olanzapine,
telenzepine, ritanserin, pyrilamine, ketanserin, GRI13808, granisetron, haloperidol, L 745870
and raclopride. The binding of [3H]clozapine was displaced by olanzapine in a
concentration-dependent manner (Fig. 1-1-A). Furthermore, the binding of [3H]clozapine
was partially displaced by telenzepine (Mi), ritanserin (5-HT2A), pyrilamine (Hi), ketanserin
(5-HT2c), GRI13808 (5-HT4), granisetron (5-HT3), haloperidol (D2), L 745870 (D4) and
raclopride (D2) (Fig. 1-1-B).
Binding properties ofolanzapine with 5-HT2A/2c, 5-HT3, 5-HT4,Hi and Mi receptors
    In mouse brain membranes, I determined the competitive displacement binding of
[3H]ketanserin, [3H]BRL-43694 (granisetron), [3H]pyrilamine, [3H]GRI13808 and
[3H]pirenzepine with graded concentrations (10-ii to 10-4 M) of unlabeled ketanserin,
granisetron, pyrilamine, GRI13808, telenzepine, pirenzepine and olanzapine. The binding
of [3H]ketanserin and [3H]pirenzepine was displaced by olanzapine in a
concentration-dependent manner (Fig. 1-2-A, 1-2-B). The binding of [3H]pyrilamine,
[3H]BRL-43694, or [3H]GRI13808 was partially displaced by olanzapine (Fig. 1-2-C, 1-2-D,
1-2-E).
16
Suppression of morphine-induced emesis by olanzapine or prochlorperazine
    Pretreatment with either olanzapine (O.03 mgtkg, subcutaneous injection) 30 min before
the injection ofmorphine (O.6 mglkg, subcutaneous injection) or prochlorperazine (O.3 mglkg
and 1.0 mglkg, subcutaneous injection) 60 min before the injection of morphine reduced the
number ofretching and vomiting behaviors induced by morphine (Fig. 1-3).
Effects of antipsychotics on catalepsy
    The results from the horizontal bar test as a measure of catalepsy were obtained at 15, 30,
45 and 60 min after the subcutaneous injection of vehicle, prochlorperazine (O.3 to 1 mglkg),
haloperidol (O.03 to O.3 mglkg), risperidone (O.Ol to O.1 mglkg), or olanzapine (O.03 to O.3
mg/kg). wnile the catalepsy scores were not affected by a single subcutaneous injection of
olanzapine (O.03 to O.3 mglkg), catalepsy was observed with the other antipsychotics within
this dose range (Fig. 1-4).
Effects of olanzapine on the morphine-induced increase in the levels of dopamine and its
metabolites in dialysate
    In the microdialysis study, the levels of dopamine and its metabolites DOPAC and HVA
in dialysate from the rat nucleus accumbens were markedly increased by the intraperitoneal
administration of morphine at 1O mgfkg compared to those under the administration of saline.
The increased levels ofdopamine, DOPAC and HVA in the nucleus accumbens following the
administration of morphine were not affected by olanzapine at O.3 mglkg
(olanzapine-morphine vs. vehicle-morphine: F(i,77) == O.1516, p = O.7086 Fig. 1-5-A, Fa77)=
O.06326, p = O.8086 Fig. 1-5-B, Fa77)= 1.851, p = O.2158 Fig. 1-5-C).
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Effect of olanzapine on the morphine-induced inhibition of gastrointestinal transit
    Morphine slowed gastrointestinal transit and this effect was not significantly altered by
the co-administration (subcutaneous injection) of olanzapine at O.03 to 1 mglkg (Fig. 1-6-A).
Olanzapine itself did not slow gastrointestinal transit at doses of O.03 and O.1 mglkg, but
significantly inhibited gastrointestinal transit at O.3 and 1 mg!kg (Fig. 1-6-B).
Effects of olanzapine on the blood glucose level
    The blood glucose level was measured after chronic treatment with olanzapine, saline or
vehicle (50/o DMSO) in mice. Hyperglycemia was not observed under treatment with
olanzapine at O.03, O.1 or O.3 mglkg (subcutaneous injection) (Fig. 1-7).
Thermal hyperalgesia induced by sciatic nerve ligation in mice
    Sciatic nerve ligation markedly decreased the latency ofpaw withdrawal in response to a
thermal stimulus on the ipsilateral side. This state of persistent pain caused by partial
ligation of the sciatic nerve was suppressed by treatment with olanzapine at O.06 mglkg (Fig.
1-8).
Changes in sleep vigilance under a neuropathic pain-like state using
electroencephalogram and electromyogram recordings
    I next investigated the changes in sleep patterns in sciatic nerve-ligated mice.
Vigilance was automatically classified offiine as wakefulness, REM sleep or non-REM sleep.
Mice with sciatic nerve ligation showed a statistically significant increase in wakefulness tp =
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O.OO09 vs. sham operated mice with vehicle, Fig. 1-9-A) and a decrease in non-REM sleep (p
==
 O.O067 vs. sham-operated mice with vehicle, Fig. 1-9-C) during the light phase. REM sleep
during the light phase was not affected by sciatic nerve ligation tp = O.2896 vs. sham-operated
mice with vehicle, Fig. 1-9-B). On the other hand, there was no statistically significant
difference in the sleep conditions during the dark phase between the two groups (wakefulness:
p = O.6170 vs. sham operated mice with vehicle, Fig. 1-9-D; REM: p = O.3936 vs. sham
operated mice with vehicle, 1-9-E; non-REM: p = O.5479 vs. sham operated mice with vehicle,
Fig. 1-9-F).
Changes in the hypnotic effects of olanzapine under a neuropathic pain-like state using
electroencephalogram and electromyogram recording
    To ascertain the hypnotic effect of olanzapine under a neuropathic pain-like state, I
performed electroencephalogram and electromyogram recording. The increased
wakefulness and decreased non-REM during the light phase in nerve-ligated mice were
significantly attenuated compared to those in sham-operated mice by the intraperitoneal
administration of olanzapine (wakefulness: p = O.OO06 vs. nerve-ligated mice with vehicle,
Fig. 1-9-A; non-REM: p == O.OOI vs. nerve-ligated mice with vehicle, Fig. 1-9-C).
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Fig. 1-1. Displacement oÅí the binding of I3H]clozapine in membranes of mouse brain without the
cerebellum by clezapine, olanzapine, telenzepine, ritanserin, pyrilamine, GRI13808, granisetron,
ketanserin, haloperidol, L 745870, or raclopride
Experiments were performed in the presence of [3H]clozapine (O.2 nM) and increasing concentrations of
either clozapine or olanzapine (A), or of telenzepine, ritanserin, pyrilamine, GRI13808, granisetron,
ketanserin, haloperidol, L 745870, or raclopride (B). The data represent the mean Å}S.E.M. of 3 to 4
samples. ICso values were determined using an analysis of variance and linear regression techniques. To
calculate the IC.so values, at least 6 drug doses were used and 3 samples were used for each dose. Values
in parentheses indicate the 959o confidence range.
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Fig. 1-2. Binding properties of olanzapine with 5-HT2Ai2c, 5-HT3, 5-HT4,Hi and Mi receptors
Displacement of the binding of the serotonin (5-HT) 2Atc receptor ligand [3H]ketanserin (A), the
muscarinic Mi receptor ligand [3H]pirenzepine (B), the H, receptor ligand [3H] pyrilamine (C), the 5-HT,
receptor ligand [3H]BRL-43694 (granisetron) (D), or the 5-HT, receptor ligand [3H]GRI13808 (E) in
membranes of mouse brain without the cerebellum by ketanserin, pirenzepine, telenzepine, pyrilamine,
granisetron, GRI13808 or olanzapine. Experiments were performed in the presence of [3H]ketanserin
(O.5 nM), [3H]BRL-43694 (05 nM), [3H]pyrilamine (05 nM), [3H]GRI13808 (05 nM), or
[3H]pirenzepine (O.5 nM) and increasing concentrations of ketanserin, granisetron, pyrilamine,
GRI13808, pirenzepine, telenzepine, or olanzapine. The data represent the mean Å}SE.M. of 3 to 4
samples. ICso values were determined using an analysis of variance and linear regression techniques. To
calculate the ICso values, at least 6 drug doses were used and 3 samples were used for each dose. Values in
parentheses indicate the 95 9o confidence range.
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Fig. 1-3. Effects of olanzapine on subcutaneous injection morphine-induced retching (A, C) and
vomiting (B J])) in ferrets
Groups of ferrets were pre-treated with olanzapine (O.O1 and O.03 mg!kg, subcutaneous injection (A, B)),
prochlorperazine (O.3 and 1.0 mglkg, subcutaneous injection (C, D)) or vehicle before the administration
of morphine (O.6 mglkg, subcutaneous injection). Animals were observed for 30 min after subcutaneous
injection of morphine. Each column represents the mean Å} S.E.M. of 9 to 10 ferrets. Statistical analyses
were performed using one-way ANOVA followed by the Bonferroni multiple comparisons test: F(3,3g)=
20.41, pÅqO.OOOI (Fig. 1-3-A), F.,,, = 11.29, pÅqO.OOOI (Fig. 1-3-B), F.,,,= 15.13, pÅqO.OOOI (Fig.
1-3-C), F{3J7)= 13.70, pÅqO.OOOI (Fig. 1-3-D) "**pÅqO.OOI vs. vehicle-saline. ###pÅqO.OOI, ## pÅqO.Ol or
#pÅqO05 vs. vehicle-morDhine.
22
***
   8
vts
zz 6
utÅr•
g34
z
:.
e
fi
Vehicle e3 eA i os3 o.1 g3 em e.e3 o.I o.o3 e.l g3 {mgtkgi
PrQchlerperazine IIaleperidgle Rigpe.xidone elanzspine
Fig. 1-4. Expression of catalepsy caused by antipsychotics in mice
Catalepsy values were obtained for 60 min after subcutaneous injection of antipsychotics. The time until
the forepaw touched the fioor or until the mouse climbed upon the bar was measured for up to 60 sec. A
score was assigned to each test based on the duration of the cataleptic posture (score 1, between 15 to 29
sec; score 2, between 30 to 59 sec; score 3, 60 sec or more). Each column represents the mean Å} S.EM.
of 6 mice. Statistical analyses were performed with one-way ANOVA followed by the Bonferroni
multiple comparisons test: Fa2,77)= 12.59,pÅqO.OOOI. *pÅqO.05, **pÅqO.Ol or ***pÅqO.OOI vs. vehicle.
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Fig. 1-5. Effect of olanzapine on the influence of intraperitoneal administration morphine on the
dialysate levels of depamine (A) and its metabolites (B, C) in the nucleus accumbens
After baseline fractions were collected, rats were pretreated with olanzapine (O.3 mglkg, intraperitoneal
administration) or vehicle 30 min before the injection of morphine (10 mglkg, intraperitoneal
administration) at time O to evoke the release of dopamine. Data are expressed as percentages of the
corresponding baseline levels with S.E.M. for 3 to 5 rats. (number of rats: olanzapine-morphine, n = 5;
vehicle-morphine, olanzapine-saline, n = 4; vehicle-saline, n = 3) Statistical analyses were performed
with two-way ANOVA followed by the Bonferroni multiple comparisons test: vehicle-saline vs.
vehicle-morphine, F(,s,)= 19.48, p = O.O069 vehicle-saline vs. vehicle-morphine, Fa77År= O.1516, p =
O.7086 olanzapine-morphine vs. vehicle-morphine (A), F(iss}= 32.57, p = O.O023 vehicle-saline vs.
vehicle-morphine, F(,,77}= O.06326, p = O.8086 olanzapine-morphine vs. vehicle-morphine (B), Fass)=
23 .42, p = O.O047 vehicle-saline vs. vehicle-morphine, Fa77)= 1.851 , p = O.2158 olanzapine-morphine vs.
vehicle-morphine (C).
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Fig. 1-6. Effect of pretreatment with olanzapine on the morphine-induced (A) inhibition of
gastrointestinal transit and the effect of olanzapine itself (B)
Each column represents the mean Å} S.E.M. of 6 mice. Ink was administered ora}ly 20 min after the
injection of morphine (O.7 mglkg, subcutaneous injection) or saiine, respectively. Groups of mice were
pretreated with olanzapine (O.03 to 1 mglkg, subcutaneous injection) at 30 min before the administration
of morphine. Gastrointestinal transit was evaluated at 20 min after the oral administration of ink.
Statistical analyses were performed with one-way ANOVA followed by the Bonferroni multiple
comparisons test: F{s.3s}= 1599, pÅqO .0001 (Fig. 1-6-A), F(,,,,= 5.778, p = O.O020 (Fig. 1-6-B). *pÅqO 05,
*** pÅqO .OO1 vs. yehicle-saline.
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Fig. 1-7. BIood glucose levels after chronic treatment with olanzapine
Hyperglycemia was not observed under treatment with olanzapine (O03, O.1 or O.3 mglkg subcutaneous
injection) for 7 days, whereas the glucose level was significantly increased by subcutaneous injection of
olanzapine at l mglkg. Values are expressed as a percentage of the control. Each column represents
the mean Å} S.E.M. of 4 mice. Statistical analyses were performed with one-way ANO VA followed by the
Bonferroni multiple comparisons test: *pÅqO .05 vs. vehicle.
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Fig. 1-8. Effect of olanzapine on thermal hyperalgesia induced by nerve ligation in mice
Groups ofmice were injected with olanzapine (O.06 mg/kg, intraperitoneal administration) or vehicle at 7
days after sciatic nerve ligation or sham operation. Thermal hyperalgesia was measured 1 h after a
single intraperitoneal administration of olanzapine or vehicle. Each column represents the mean Å}
S.E.M. of 6 to 8 mice. (number of mice: sham-vehicle, n = 6; ligation-yehicle, ligation-olanzapine, n =
8) Statistical analyses were performed with Student's t-test. *"p = O.OO17 vs. sham-vehicle, #p = O.031
vs. nerve ligation-vehicle.
27
E-
; g
x'
,g
=
e
s
A
1gsu;
StPB
fiao
4ge
2ag
  a
Wakeful.ness 2 Ligtst phase
SkaB} Llgwhan Sham LigatioR
B
see
se
fie
4e
!e
KÅíM s4 Light pha,se
Sharn Llgntien Shaxn Ligatien
Veh.icle Olanzftpine
c
Vehie,le Olanzapine
lgec
seg
6og
4ti-e
2oe
lle•m-RErvl S Light pkase
Shame !.igAlian ShArn LigatibA
N'eb,lcl•e Olaltzaplfie
F
'g
wE
aF/.
a
r.
-
D
leee
 see
 see
 4eij
 ;ffo
"eakefniness g Park phftse
Sham Lig,ataen Shnm Ligsti•on
x
  Ieg
  ggE•
'g
el.-
 6e
E
"-'
m 4e
r.
- 2e
   e
ms-.M S Dark phase
Sham Lig,atien Sham Lagala•efi
F
leE}{)
see
sag
4ee
lee
liett-RE.M g Dark phase
Skem LSgntlon Sham gi g. atien
Vehiele O]Anzapi.be Vehlel-e OlaRzgpine Vehiel-e Olanzapinff
Fig. 1-9. Changes in sleep vigilance related to the hypnotic effects of olanzapine under a
neuropathic pain-like state as determined by electroencephalogram and e}ectromyogram recordings
Sleep-wake states following the injection of vehicle (5 9o dimethyl sulfoxide) or olanzapine at 7 days after
sciatic nerve ligation. Vehicle or olanzapine (O.06 mglkg, intraperitoneal administration) was injected
once at 8:OO AM. The total time spent in wakefulness in the light phase (A) and the dark phase (D), rapid
eye movement (REM) sleep in the light phase (B) and in the dark phase (E) and non-REM sleep in the
light phase (C) and in the dark phase (F) was determined by electroencephalogram and electromyogram
recording. Each column represents the mean Å} S.E.M. of 5 mice. Statistical analyses were performed
with Student's t-test. **p = O.O067, """p = O.OO09 vs. sham-vehicle, ##p = O.OO1 , ###p = O.OO06 vs. nerve
ligation-vehicle.
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                                  Discussion
    The use of opioids for pain management is often associated with nausea and vomiting.
Opioids induce emesis by stimulating the CTZ in the brainstem and by enhancing vestibular
sensitivity 40'4i). Although several compounds are known to act on receptors in the CTZ,
opioid-induced nausea and vomiting are attributable primary to the transmission of dopamine.
Many clinicians consider that typical antipsychotics such as prochlorperazine and haloperidol,
which mainly act as dopamine D2 receptor antagonists, are the dmgs of choice for preventing
the nausea and vomiting induced by morphine 42-44). However, such compounds often
produce extrapyramidal symptoms 20).
    Olanzapine is an atypical thienobenzodiazepine antipsychotic that is clinically indicated
for schizophrenia and mania 45). It blocks multiple neurotransmitters, including
dopaminergic, serotonergic, adrenergic, histaminergic and muscarinic receptors 46). In the
present binding study, olanzapine showed the highest affinity for muscarinic Mi receptors.
To understand its affinity in greater detail, I investigated the affinity of olanzapine toward
serotonin 5-HT2A!2c, 5-HT3, histamine Hi, dopamine D2, dopamine D4 and 5-HT4 receptors.
01anzapine also showed affinity for each of these receptors. Due to its effect on several
neurotransmitters that are associated with nausea and vomiting, I expected that olanzapine
would have potential as an antiemetic medication. In a behavioral study, I found that
morphine-induced nausea and vomiting were dose-dependently decreased by pretreatment
with olanzapine at a dose that was almost 11200 of that at which an antipsychotic effect is
observed 47), whereas olanzapine at a dose that had antiemetic effects failed to induce
catalepsy. However, although the dopamine D2 receptor antagonist prochlorperazine
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suppressed morphine-induced nausea and vomiting, it did so at a dose that caused a
dose-dependent increase in the expression ofcatalepsy. Furthermore, olanzapine had no effect
on the morphine-induced release of dopamine in the nucleus accumbens. Muscarinic Mi
receptors have been suggested to be responsible for the opioid-induced stimulation of the
vestibular apparatus 5). In addition, sensory input from the vestibular apparatus to the
vomiting center follows muscarinic Mi receptor pathways. Taken together with the fact that
olanzapine showed the highest affmity toward muscarinic Mi receptors, these findings
suggest that, although the exact mechanism by which olanzapine suppresses
morphine-induced emesis remains unclear, muscarinic Mi receptors may be a critical target
for morphine-induced emesis. To prove our hypothesis, I next investigated whether the
selective muscarinic Mi receptor antagonist trihexyphenidyl could affect morphine-induced
nausea and vomiting. Trihexyphenidyl significantly suppressed morphine-induced retching
and vomiting in ferrets (data not shown), which indicates that Mi receptors play an important
role in the opioid-sensitive emetic pathway. However, trihexyphenidyl significantly
enhanced the morphine-induced increase in the release of dopamine in the nucleus accumbens
(data not shown). IfI consider the risk of the overexcitation of dopamine transmission with
the use of drug combinations, a specific Mi receptor antagonist might not be a better choice as
an adjunct agent in combination with opioids. Because olanzapine acts not only on
muscarinic Mi receptors, but also partly on histamine Hi and dopamine D2 receptors as an
antagonist 28), it is likely that olanzapine at a dose lower than that at which it has antipsychotic
effects could be usefu1 for strongly preventing opioid-induced emesis without severe
side-effects.
    Constipation is another adverse effect oftreatment with morphine. In the present study,
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olanzapine at doses that had antiemetic effects had no effect on the morphine-induced
inhibition of gastrointestinal transit. This may be attributable to the high central transitivity
of olanzapine.
  Long-term treatment with olanzapine is most commonly associated with increased weight
gain, obesity, and diabetes mellitus 48). Therefore, I evaluated the effect ofchronic treatment
with olanzapine on blood glucose. As a result, hyperglycemia was not observed during
treatment with olanzapine at a dose at which it had an antiemetic effect (O.03 mglkg).
However, long-term treatment with olanzapine at a dose of 1 mglkg was associated with a
slight but statistically significant increase in blood glucose levels. These findings support the
idea that olanzapine may have a wide margin of safety when used as an antiemetic.
    With regard to sleep disturbance in severe pain, I confirmed that mice with sciatic nerve
ligation showed a statistically significant increase in wakefulness and a decrease in non-REM
sleep during the light phase. Under the current conditions, treatment with olanzapine at
doses at which the pain threshold was restored improved the sleep disturbance after sciatic
nerve ligation. Histamine and serotonin are the key neurotransmitters that regulate
wakefulness, and their receptors are the ultimate targets of many wakefulness- and
sleep-promoting drugs. In particular, histamine Hi receptor antagonist and serotonin
5-HT2Ai2c receptor antagonist are known to shift one's arousal state from hyperactivity to
sleep 49). Therefore, the improvement of sleep disturbance during treatment with olanzapine
may result from the agent's antagonistic effects toward histamine Hi and serotonin 5-HT2Af2c.
    Overall, the current results suggest that olanzapine may be very usefu1 for the treatment
of morphine-induced emesis, reducing neuropathic pain, and for improving pain-related sleep
disturbance. Against a background ofincreasing concern about "polypharmacy", olanzapine
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can be used as a single adjunct agent, and can be given in a state-dependent dose, which
should improve the QOL for patients while greatly reducing the side-effects of opioids.
    In conclusion, I propose that treatment with olanzapine may lead to a new strategy for
controlling emesis when patients are given opioid medications.
    In addition, the current study provides evidence that olanzapine may be a useful agent
for improving the sleep disturbance caused by neuropathic pain that is observed in some
patients with cancer.
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Chapter 2
Olanzapine suppresses the rewarding and discriminative stimulus effects
induced by morphine
33
Introduction
    Morphine has been used as a "gold standard" for the treatment of patients who suffer
moderate to severe cancer pain 27). When morphine is used to treat pain, the adverse effects
of opioids, such as emesis, constipation, drowsiness, hallucination and delirium must be
reduced to improve the QOL of the patient. Against this background, antipsychotic drugs,
many of which are dopamine receptor antagonists, have been used to reduce opioid-induced
emesis and other dopamine-related side effects, including hallucination and delirium.
However, the adverse effects of antipsychotic drugs, such as extrapyramidal symptoms, can
be a disadvantage of their use 42).
    Ever since chlorpromazine was shown to have an antipsychotic effect more than 50
years ago, the number of antipsychotic medications has continued to grow. Typical or
first-generation antipsychotic drugs such as chlorpromazine and haloperidol are effective for
the treatment of delusions and hallucinations, while such compounds have a high risk of
adverse extrapyramidal side effects 50). Atypical or second-generation antipsychotic drugs,
especially chlorpromazine derivatives such as clozapine and olanzapine, have been developed
and used for the treatment of dopamine-, serotonin-, acetylcholine-, andror histamine-related
symptoms, and show a relative lack of extrapyramidal side effects 5i). Opioid-induced
changes in emotionality and multiple physiological functions are likely to result from the
regulation ofmultiple neurotransmitters.
    Olanzapine is an atypical thienobenzodiazepine antipsychotic that blocks dopaminergic,
serotonergic, adrenergic, histaminergic, and muscarinic receptors for multiple
neurotransmitters. I previously demonstrated that olanzapine clearly showed affrinities for
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these receptors in the rodent brain and was effective for the treatment of morphine-induced
emesis, for reducing neuropathic pain, and for improving pain-related sleep disturbance 52). I
proposed that olanzapine could be used as a single adjunct agent against a background of
increasing concern about "polypharmacy", and can be given in a state•-dependent dose, which
should improve the QOL for patients while greatly reducing the side-effects of opioids.
    In the present study, I used rodents to further investigate whether olanzapine could
suppress the hyperlocomotion, rewarding effect and discriminative stimulus effect induced by
morphine, which are all considered to reflect the abuse potential or psychoactive effects of
pt-opioids.
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                           Materials and Methods
Animals
    In the present study, male Institute of Cancer Research mice (20 - 25 g) (Tokyo
Laboratory Animals Science Co. Ltd, Tokyo, Japan) and seven male Fischer 344 rats (Charles
River Japan Inc., Atsugi, Japan) maintained at 200 - 230 g (80 O/o free-feeding weight) were
used. Food and water were available ad libitum for mice, and water was available ad libitum
for all of the rats in their individual home cages. Animals were housed in a room maintained
at 22 Å} 1 CO with a 12-h light-dark cycle (lights on 8:OO AM - 8:OO pM). The present study
was conducted in accordance with the Guiding Principles for the Care and Use ofLaboratory
Animals at Hoshi University, as adopted by the Committee on Animal Research of Hoshi
University. Every effort was made to minimize the numbers and any suffering of animals
used in the following experiments.
Rota-rod assay
    To determine the doses of olanzapine to be tested, which would not affect animal
behavior, I first used a rota-rod assay. The motor coordination produced by olanzapine in
mice was evaluated in terms of the time until they fell from a rota-rod at 8 rpm (KN-95;
Natsume Seisakusyo, Co., Ltd., Tokyo, Japan). The apparatus consists ofa rotating acrylic
rod (3 cm in diameter) divided into four 8-cm sections by circular Plexiglas dividers (18 cm
high). First, mice were trained to be able to walk on the rota-rod for 180 s. This training
was performed for 3 days. On the day after the final training session, the time until the
mouse fell from the rota-rod was measured for up to 180 s at 30 min after the administration
of olanzapine (O.03 - 1 mg/kg, s.c.). In addition, any behavioral changes were also observed
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by comparison to the vehicle control.
Locomotor activity
    The locomotor activity of mice was measured by an ambulometer as described
previously 53). Briefly, a mouse was placed in a round tilting-type activity cage 20 cm in
diameter and 19 cm high. Any slight tilt of the activity cage, which was caused by
horizontal movement of the mouse, was detected by three microswitches. The total activity
counts in each 10-min segment were automatically recorded for 180 min following the
administration ofsaline or morphine (10 mgtkg, s.c.). Olanzapine (O.03, O.1 and O.3 mglkg,
s.c.) was administered 30 min prior to treatment with morphine.
Place conditioning
    Place-conditioning studies were conducted using a shuttle box (15 Å~ 30 Å~ 15 cm: w Å~ l Å~
h) composed of an acrylic resin board divided into two equal-sized compartments 25). One
compartment was white with a textured floor and the other was black with a smooth floor to
create equally inviting compartments. The place-conditioning schedule consisted of three
phases (pre-conditioning test, conditioning, and post-conditioning test). The pre-conditioning
test was performed as follows: the partition separating the two compartments was raised to 7
cm above the floor, a neutral platform was inserted along the seam separating the
compartments, and mice that had not been treated with either dmgs or saline were then placed
on the platform. The time spent in each compartment during a 900-s session was then
recorded automatically using an infrared beam sensor (KN-80, Natsume Seisakusyo Co. Ltd,
Tokyo, Japan). Conditioning sessions (three for morphine: three for saline) were started the
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day after the pre-conditioning test and conducted once daily for 6 days. Mice were
pretreated with olanzapine (O.1 or O.3 mglkg, s.c.) or vehicle 30 min before the injection of
morphine or saline. Immediately after the injection ofmorphine (5 mglkg, s.c.), the animals
were placed in the compartment opposite that in which they had spent the most time in the
pre-conditioning test for 1-h. On alternate days, the animals were treated with saline after
pretreatment with olanzapine or vehicle and placed in the other compartment for 1-h. On the
day after the final conditioning session, a post•-conditioning test that was identical to the
pre-conditioning test was performed.
Drug diserimination procedure
    Experiments were conducted in operant-conditioning chambers (model ENV-O08; Med
Associates Inc., St. Albans, VT, USA) equipped with two levers and a food cup mounted
midway between the levers. White lamps were installed above each ofthe levers. White
noise was used to mask extraneous sound. Reinforcement consisted of45-mg food pellet
(Bio-Serv Inc., Frenchtown, NJ, USA).
    Discrimination training was performed as described previously 54), Briefly, before they
were trained to discriminate between drugs and saline, all rats were trained to press a lever.
Training began under a reinforcement schedule of fixed ratio 1 (FR 1), in which the rat was
presented with a food pellet each time it pressed a lever. When reinforcement was provided,
the light above the lever was illuminated. The FR requirement for food reinforcement was
gradually increased to a value of 10. After the response rates had stabilized under FR 10,
rats were trained to discriminate between 3.0 mglkg of morphine and saline. In the
discrimination training, training morphine (D) and saline (S) were administered in a
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session-to-session sequence of DDSS (double alternation schedule), and the assignment of
left and right levers to dmg and saline states was counter-balanced. Rats were required to
respond on the stjmulus-appropriate lever to obtain reinforcement; there were no programmed
consequences for responding on the incorrect lever. Substitution tests were only performed
after the discrimination criterion described below had been satisfied for at least five
consecutive daily discrimination-training sessions (accuracy of at least 83 O/o and fewer than
12 responses to obtain the first reinforcement).
    After the animals attained the criterion, a dose-response test was initiated; test sessions
were performed only when FRF s12 for at least three consecutive discrimination training
sessions. In the dose-response test, rats were placed in the operant box until they had made 1O
responses on either lever or 5 min had elapsed. In the combination test, doses ofolanzapine
that produced less than 20 O/o drug-lever responses and did not affect the response rates in the
generalization tests were used in generalization tests. The pretreatment time and doses of
drugs used were 30 min and O.03-O.3 mg!kg of olanzapine. If the rats did not make 10
responses during each component, the response was judged to have been disrupted.
Drugs
    The drugs used in the present study were morphine hydrochloride (Daiichi-Sankyo,
Tokyo, Japan) and olanzapine (Toronto Research Chemicals Inc., Toronto, Ontario, Canada).
Morphine was dissolved in saline and olanzapine was dissolved in DMSO: Tween80: saline
(5: 5: 90). All drugs were administrated in a volume of 1.0 mllkg (rats) or 10 mllkg (mice).
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Statistical Analysis
    Data are expressed as the mean with S.E.M. The statistical significant of differences
between the groups was assessed by a one-way analysis of variance (ANOVA) followed by
the Bonferroni multiple comparisons test or two-tailed paired t-test. All statistical analyses
were performed using Prism software (version 5.0a, GraphPad Software, Inc., La Jolla, CA).
A p value ofÅq O.05 was considered to refiect significance.
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Results
Motor coordination produced by olanzapine in the mouse rota-rod assay
    In the rota-rod test, olanzapine (1 mglkg, s.c.) produced significant motor impairment in
mice compared to vehicle-treated mice (F(3,23)=10.19, pÅqO.OOOI), whereas olanzapine at
doses ofO.03 to O.3 mglkg did not induce motor dysfunction (Fig. 2-1).
Suppression of morphine-induced hyperlocomotion by pretreatment with olanzapine at
doses that failed to induce motor dysfunction
    A single injection of morphine at 10mg!kg (s.c.) produced a significant increase in
locomotion. Pretreatment with olanzapine at O.03, O.1 and O.3mglkg (s.c.) induced a
dose-dependent suppression of this morphine-induced hyperlocomotion, and these effects of
olanzapine were significant at all ofthe doses tested (pÅqO.05 for O.03, pÅqO.Ol for O.1, pÅqO.OOI
for O.3 vs. vehicle pretreatment) (Fig. 2-2A). In contrast, locomotion activity was not
changed by olanzapine itself at dose of O.3 mglkg with saline.
Inhibition of morphine-induced place preference by pretreatment with olanzapine at a
dose that did not induce motor impairment
    Consistent with our previous results with morphine using the same procedure, morphine
(5 mg/kg, s.c.) produced a significant place preference in mice. A significant place
preference or place aversion was not observed by olanzapine itself at the dose of O.3 mglkg
with saline. Under these conditions, pretreatment with olanzapine at O.3mgfkg (s.c.)
significantly suppressed the rewarding effects of morphine (Fig 2-2B).
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Suppression of the drug discriminative effect of morphine by olanzapine at doses that
failed te induce motor dysfunction
    Rats required 23 sessions to acquire morphine-saline discrimination. Once rats attained
the criterion, morphine-saline discrimination stabilized and was maintained with a high
degree of accuracy. During the dose-response tests, morphine at O.3-3.0 mglkg (s.c.)
produced a dose-dependent increase in morphine-appropriate responses in all of the rats (Fig.
2-3A). In the combination test, olanzapine dose-dependently and significantly attenuated the
discriminative stimulus effects ofthe training dose (3.0 mglkg) ofmorphine without affecting
the response rates (P=O.0294 vs. saline pretreatment) (Fig. 2-3B).
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Discussion
    In humans, morphine induces several kinds of subjective and psychotic effects, while in
animals morphine clearly has reinforcinglrewarding effects. The place-conditioning
procedure is used to evaluate rewarding and aversive effects 25). In addition, the evaluation
of hyperlocomotion induced by morphine has also been used to assess the pharmacological
mechanisms that underlie the abuse of morphine 53). A large and growing body of evidence
has demonstrated that activation of the dopaminergic, especially mesolimbic, system plays a
crucial role in the expression of both hyperlocomotion and the reinforcinglrewarding effects
of opioids 55-57). In the present study, I clearly confirmed that morphine at a range of 5 to 10
mglkg induced significant hyperlocomotion and conditioned place preference in mice, which
reflected the abuse potential of morphine in rodents.
    Even though pt-opioids have potential for abuse andlor addiction clinical studies have
shown that abuse and addiction do not usually occur when pt-opioids are used appropriately to
control pain 58). I have proposed that the abuse potential of morphine is potently suppressed
under chronic pain in rodents 59'6i). However, over the past decade there has been some
concern regarding the abuse of and addiction to pt-opioids caused by the inappropriate use,
misuse or overdose of prescription opioids 62). Dopamine receptor antagonists have been
commonly used to reduce the adverse reactions to pt-opioids including delusions and
hallucinations i9). Olanzapine is an atypical antipsychotic that is clinically indicated for
schizophrenia and mania. It blocks multiple neurotransmitters 63'64). In the present study, I
found that olanzapine at O.3 mglkg, which did not induce motor coordination significantly
suppressed the hyperlocomotion and rewarding effects induced by morphine. In our
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preliminary study, treatment with olanzapine at O.3 mglkg failed to reduce the antinociceptive
effect of morphine. Furthermore, the delay in colonic expulsion induced by morphine was
not affected by O.3 mglkg of olanzapine, which indicated that olanzapine did not exacerbate
morphine-induced constipation. Taken together, these findings support the idea that
olanzapine may have a wide margin ofsafety when used as an adjuvant for p-opioids.
    In a previous binding study in brain tissue, I found that olanzapine exhibited the highest
affinity for muscarinic Mi receptors and also showed affinity toward serotonin 5-HT2A!2c,
5-HT3, histamine Hi, dopamine D2, dopamine D4 and 5-HT4 receptors. In light of this
multiple binding property, I previously documented in an in vivo study that olanzapine
dose-dependently decreased morphine-induced nausea and vomiting that are caused through
various mechanisms 52).
    Muscarinic Mi receptors have been suggested to be responsible for the enhancement of
opioid-stimulated dopaminergic transmission related to the aggravation of drug addiction 65).
Since olanzapine showed the highest affinity toward muscarinic Mi receptors, it is reasonable
to wonder if olanzapine could aggravate the abuse potential of m-opioids. This contention
can be supported by the fact that the selective muscarinic Mi receptor antagonist
trihexyphenidyl significantly enhanced the morphine-induced increase in the release of
dopamine in the nucleus accumbens (our preliminary study; data not shown), which indicates
that Mi receptors play an important role in opjoid addictjon. However, in the present study,
olanzapine did not enhance either the hyperlocomotion or place preference produced by
morphine. Although the exact mechanism by which olanzapine suppresses morphine's
abuse profile remains unclear, this phenomenon may result from the fact that olanzapine acts
not only on muscarinic Mi receptors, but also partly on serotonin 5-HT2A!2c, 5-HT3, histamine
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Hi, dopamine D2, dopamine D4 and 5-HT4 receptors as an antagonist.
    Morphine has subjective effects (e.g., "strength of drug effect," "sedated," "heavy or
sluggish feeling" and "high") in healthy volunteers 66). Furthermore, morphine can induce
drowsiness, hallucination and delirium, which have been considered to be important cues for
the subjective effects ofmorphine 67'68). To assess the subjective effects in humans, animal
models for studying the components of drug action that bear on the subjective effects have
been developed. A methodology which has considerable potential in this regard is the drug
discrimination procedure 26). However, little is known about the mechanism of the
discriminative stimulus effects of morphine in animals. In the present study, olanzapine at
O.3 mgfkg significantly attenuated the discriminative stimulus effects of the training dose of
morphine in rats. It should be emphasized that neither the Di receptor antagonist SCH23390,
the D2 receptor antagonist haloperidol nor their combination affected the discriminative
stimulus effects of morphine in rats that had been trained to discriminate between 3.0 mglkg
morphine and saline 69). Therefore, I hypothesize that the blockade of neurotransmitters
other than dopamine receptors by olanzapine at this dose may contribute to attenuate the
discriminative stimulus effects ofmorphine.
    In conclusion, I found that olanzapine at a dose that failed to induce motor dysfunction
suppresses the hyperlocomotion, place preference and discriminative stimulus effect induced
by morphine. These results further provide evidence that co-treatment with olanzapine may
be very usefu1 as an adjuvant for pain control by pt-opioids.
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Generat Conclusion
The above findings led to the following conclusions:
In Chapter 1:
    In the present study, I investigated whether the atypical antipsychotic olanzapine at doses
lower than those that induce catalepsy could suppress morphine-induced emesis with a few
side-effects. Additionally, I also examined if olanzapine could improve the sleep
disturbance under a neuropathic pain-like state. Morphine-induced nausea and vomiting
were dose-dependently decreased by olanzapine. However, olanzapine at this dose did not
induce either catalepsy or hyperglycemia. Furthermore, olanzapine at doses that had
antiemetic effects had no effect on the morphine-induced release of dopamine or inhibition of
gastrointestinal transit, suggesting that the blockade of multiple receptors by olanzapine can
suppress the emetic effect ofmorphine without producing adverse side-effects. Moreover,
olanzapine almost completely alleviated the sleep disturbance under neuropathic pain. The
present results suggest that treatment with olanzapine may pave the way for a new strategy for
controlling "total pain" when patients are given opioid medication.
In Chapter 2:
    In the present study, I used rodents to investigate whether olanzapine could suppress the
hyperlocomotion, rewarding effect and discriminative stimulus effect induced by morphine,
which are all considered to reflect the abuse potential or psychoactive effects of morphine.
Olanzapine at doses that failed to induce motor incoordination produced a dose-dependent
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reduction in the hyperlocomotion and place preference induced by morphine in mice.
Furthermore, the discriminative stimulus effect induced by morphine in rats was
dose-dependently and significantly attenuated by olanzapine at a dose that did not suppress
the response rate. These results suggest that co-treatment with olanzapine at a dose that
does not induce motor incoordination along with morphine could be very usefu1 for
preventing the abuse potential andlor psychoactive effects ofmorphine.
Conctuding remarks:
    These results indicate that olanzapine may be very usefu1 for the treatment of
morphine-induced emesis, and for reducing neuropathic pain, improving pain-related sleep
disturbance and reducing the abuse potential. Against a background of increasing concern
about "polypharmacy", olanzapine can be used as a single adjunct agent, and can be given in
a state-dependent dose, which should improve the QOL for patients while greatly reducing
the side-effects of morphine.
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